Macquarie initiated coverage on BeiGene with a new price target
$BGNE
Biotechnology: Pharmaceutical Preparations
Health Care
Macquarie initiated coverage of BeiGene with a rating of Outperform and set a new price target of $259.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/18/2024 | $288.00 | Mkt Outperform | JMP Securities |
| 2/6/2024 | $185.00 | Overweight | JP Morgan |
| 9/12/2023 | $259.00 | Outperform | Macquarie |
| 8/17/2023 | $287.00 | Buy | Jefferies |
| 7/17/2023 | $275.00 | Buy | Citigroup |
| 6/30/2023 | $335.00 → $196.00 | Outperform → Mkt Perform | Bernstein |
| 1/12/2023 | $308.00 | Buy | Daiwa Securities |
| 10/13/2022 | $205.00 | Neutral → Buy | Guggenheim |
JMP Securities initiated coverage of BeiGene with a rating of Mkt Outperform and set a new price target of $288.00
JP Morgan resumed coverage of BeiGene with a rating of Overweight and set a new price target of $185.00
Macquarie initiated coverage of BeiGene with a rating of Outperform and set a new price target of $259.00
SC 13D/A - BeiGene, Ltd. (0001651308) (Filed by)
SC 13G/A - BeiGene, Ltd. (0001651308) (Subject)
SC 13G/A - BeiGene, Ltd. (0001651308) (Subject)
Julia Wang Named Chief Financial Officer Beginning December 2, 2024 BURLINGTON, N.C., Nov. 19, 2024 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today that Executive Vice President and Chief Financial Officer (CFO) Glenn Eisenberg will retire from the company and Julia Wang will join on December 2, 2024, as Executive Vice President and Chief Financial Officer. Mr. Eisenberg will remain at Labcorp as Special Advisor to the CEO through April 2025 to ensure a seamless transition of his current role and assist with strategic initiatives underway within the company.
BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160, SSE: 688235))), a global oncology company, today announced the appointment of Shalini Sharp to its Board of Directors and as a member of the Board's Audit Committee, effective September 27, 2024. "We are fortunate to welcome Shalini to the Board of Directors at this pivotal moment of growth," said John V. Oyler, Co-Founder, Chairman and CEO of BeiGene. "The Board is looking forward to collaborating with Shalini, whose extensive experience in leading innovative global pharmaceutical companies will be invaluable as we enter new markets, advance our pipeline of groundbreaking cancer therapies, and embark on a transformative growth phase. Her financial
BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160, SSE: 688235))), a global oncology company, today announced the appointment of Matt Shaulis as General Manager of North America, effective September 25. "We are excited to welcome Matt, who brings a wealth of global pharmaceutical experience, including leading the commercialization of blockbuster franchises at multiple multinational companies," said John V. Oyler, Co-Founder, Chairman and CEO at BeiGene. "Matt's management will be pivotal as we continue our leadership in hematology with BRUKINSA and replicate that success in solid tumors, with a deep and exciting pipeline of innovative therapies." Mr. Shaulis is a global commercial executive with ov
8-K - BeiGene, Ltd. (0001651308) (Filer)
8-K - BeiGene, Ltd. (0001651308) (Filer)
SCHEDULE 13D/A - BeiGene, Ltd. (0001651308) (Filed by)
4 - BeiGene, Ltd. (0001651308) (Issuer)
4 - BeiGene, Ltd. (0001651308) (Issuer)
3 - BeiGene, Ltd. (0001651308) (Issuer)
Julia Wang Named Chief Financial Officer Beginning December 2, 2024 BURLINGTON, N.C., Nov. 19, 2024 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today that Executive Vice President and Chief Financial Officer (CFO) Glenn Eisenberg will retire from the company and Julia Wang will join on December 2, 2024, as Executive Vice President and Chief Financial Officer. Mr. Eisenberg will remain at Labcorp as Special Advisor to the CEO through April 2025 to ensure a seamless transition of his current role and assist with strategic initiatives underway within the company.
Agreement provides for generic entry of innovative BTK inhibitor in 2037 BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160, SSE: 688235)), a global oncology company which intends to change its name to BeOne Medicines Ltd., today announced it has entered into a settlement agreement with MSN Pharmaceuticals, Inc. and MSN Laboratories Private Ltd. resolving patent litigation related to MSN's Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of BRUKINSA® (zanubrutinib) in the U.S. Under the terms of the agreement, MSN will not be able to sell a generic version of BRUKINSA earlier than June 15, 2037, subject to potential acceleration or extension under certain custom
New name reflects Company's bold vision to eradicate cancer by harnessing the transformative power of global collaboration and multisectoral partnerships Company will change its Nasdaq ticker to ONC BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160, SSE: 688235)), a global oncology company, today announced its intent to change the Company's name to BeOne Medicines Ltd., confirming its commitment to develop innovative medicines to eliminate cancer by partnering with the global community to serve as many patients as possible. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241114671168/en/(Graphic: Business Wire) "Cancer, a leading ca
BeiGene acquires exclusive option for global license to investigational antibody drug conjugate; DualityBio to continue preclinical research activities and support Investigational New Drug filing BeiGene (NASDAQ:BGNE, HKEX: 06160, SSE: 688235))), a global biotechnology company, and DualityBio, a next-generation ADC company, today announced an agreement for BeiGene to acquire an exclusive option for a global clinical and commercial license to an investigational, preclinical ADC therapy for patients with select solid tumors. "With one of the industry's leading global oncology research teams, we are investing in highly impactful therapeutic modalities such as ADCs that complement our dynam
Final ALPINE Progression-Free Survival (PFS) results simultaneously published in The New England Journal of Medicine and presented at late-breaking session at 64th American Society of Hematology Annual Meeting BRUKINSA demonstrated superiority to IMBRUVICA in both PFS and Overall Response Rate with fewer cardiac events BeiGene (NASDAQ:BGNE, HKEX: 06160, SSE: 688235))) a global biotechnology company, today presented the final progression-free survival (PFS) analysis of the ALPINE trial demonstrating superior efficacy and a favorable cardiac safety profile for patients receiving BRUKINSA® as compared to IMBRUVICA® in a global phase 3 trial in patients with relapsed/refractory (R/R) chronic
BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160))), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that it will host an investor conference call and webcast on Wednesday, August 25, 2021, at 9:30 a.m. ET to discuss the Company's early development pipeline and research. A live webcast of the conference call can be accessed from the investors section of BeiGene's website at http://ir.beigene.com or http://hkexir.beigene.com. An archived replay will be available after the event for 90 days. About BeiGene BeiGene is a global, science-driven biotechnology company